Tapentadol can produce euphoria, and people who misuse it do report a recognizable opioid high, but the subjective experience differs from what most users expect of a Schedule II painkiller. Because tapentadol works through two distinct brain pathways simultaneously rather than leaning heavily on a single opioid mechanism, the “high” tends to be milder per milligram than drugs like oxycodone or hydromorphone. That does not make recreational use safe. Tapentadol carries real risks of dependence, respiratory depression, seizures, and death, especially when mixed with other substances.
How Tapentadol Works in the Brain
Tapentadol was the first centrally acting painkiller approved in the United States that combines two mechanisms in one molecule: it activates mu-opioid receptors and it blocks the reuptake of norepinephrine (noradrenaline).1PubMed. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor These two actions work together in a synergistic way, meaning relatively moderate activity at each target site is enough to produce strong pain relief.2PubMed. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol That synergy is the key to understanding why the “high” from tapentadol doesn’t feel quite like a traditional opioid: the drug doesn’t need to slam the opioid receptors as hard as morphine does to achieve meaningful pain control, so the purely opioid component of the experience is somewhat muted at therapeutic doses.
Unlike tramadol, which is sometimes compared to it, tapentadol doesn’t need to be converted by liver enzymes into an active form before it works. It acts directly.3PubMed. Comparative pharmacology and toxicology of tramadol and tapentadol This means the onset of effects is more predictable and less dependent on a person’s individual genetics. For someone chasing a high, that predictability is part of the appeal. For clinicians, it’s a double-edged sword: patients get reliable pain relief, but the reliable onset also makes the drug easier to titrate upward when misused.
What the Euphoria Actually Feels Like
Case reports from people who developed tapentadol dependence describe the euphoria in ways that overlap with but are not identical to a classic opioid high. In one published case series, a man who switched from codeine to tapentadol found it “more potent” and reported euphoria along with unusual visual effects, describing different colors appearing in his normal visual field. He developed craving and tolerance within a month and escalated from 50 mg to 400 mg daily.4The Primary Care Companion for CNS Disorders. Tapentadol Dependence: A Case Series Another individual in the same case series, who initially tried tapentadol to quit alcohol, experienced euphoria, a perception of time moving faster, and increased hypnagogic hallucinations (vivid imagery at the edge of sleep). His tolerance spiraled: within two years, he had escalated from 100 mg to 6,000 mg daily.5The Primary Care Companion for CNS Disorders. Tapentadol Dependence: A Case Series
Those visual and perceptual effects aren’t typical of pure opioid agonists like morphine or oxycodone, and they likely reflect the norepinephrine component. Norepinephrine is involved in arousal, alertness, and sensory processing, so flooding the brain with it alongside opioid activation creates a different cocktail of effects than most people associate with painkillers. The high isn’t just sedating warmth; it can have a stimulating, perceptually altered edge.
Abuse Potential Compared to Other Opioids
Population-level surveillance data consistently show that tapentadol abuse rates run lower than most other Schedule II opioids, though the picture comes with caveats. A large postmarketing study found that tapentadol abuse was reported significantly less often than all comparator opioids, including oxycodone, hydrocodone, and morphine. When adjusted for the number of prescriptions written, tapentadol’s abuse rates were among the lowest of the Schedule II drugs studied.6PubMed. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment A separate analysis using multiple surveillance systems reached a similar conclusion: abuse event rates per capita were significantly lower than all other opioids examined.7PubMed. Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System
An Australian surveillance study reinforced this. Among people who inject drugs (a high-risk population), lifetime use of the sustained-release tapentadol formulation was reported by only about 1.5% of the sample, with very few reporting non-prescribed use or injection. Self-reported non-fatal overdose following tapentadol use was under 1%.8PubMed. Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study
These numbers look reassuring on the surface, but they deserve a closer look. Tapentadol has far fewer prescriptions in circulation than oxycodone or hydrocodone, so raw abuse counts will naturally be lower. When the RADARS analysis adjusted for drug availability, tapentadol’s abuse rates were lower than most Schedule II opioids but were not the absolute lowest.9PubMed. Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System The drug’s lower profile on the street may partly reflect limited supply and lower name recognition, not just inherently lower appeal.
How Tapentadol Compares to Tramadol
People often lump tapentadol and tramadol together because both combine opioid activity with monoamine effects. In practice, they are quite different drugs. Tapentadol is roughly two to three times more potent than tramadol and two to three times less potent than morphine.10PubMed Central. Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients Tapentadol’s opioid receptor activity is several-fold greater than tramadol’s, and it has prominent norepinephrine effects with minimal serotonin involvement, whereas tramadol leans more heavily on serotonin reuptake inhibition.11PubMed. Mechanistic and functional differentiation of tapentadol and tramadol
For someone seeking a high, those differences matter. Tapentadol delivers a more recognizably opioid experience than tramadol does, and it does so on its own without needing liver enzymes to convert it. Tramadol’s “high” is famously inconsistent because some people lack the specific enzyme needed to activate it fully. Tapentadol doesn’t have that variable, which makes it more reliably psychoactive across different people.12PubMed. Comparative pharmacology and toxicology of tramadol and tapentadol At the same time, tapentadol carries more typical opioid side effects than tramadol, including greater risk of constipation, respiratory depression, and abuse.13PubMed Central. Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients
Tolerance and Dependence
Tolerance to tapentadol’s pain-relieving effects develops with repeated use, just as it does with all opioids. Animal studies that compared tolerance development across drugs found that chronic tapentadol use led to tolerance at a rate similar to tramadol but much less than morphine.14PubMed. Nitric oxide modulates tapentadol antinociceptive tolerance and physical dependence That’s worth noting, but slower tolerance development doesn’t mean no tolerance development. The case reports of people escalating from therapeutic doses to thousands of milligrams daily make clear that recreational users can blow past tolerance rapidly when chasing euphoria.
Physical dependence follows a somewhat unusual pattern. Tapentadol is associated with a relatively low frequency of withdrawal symptoms after abrupt discontinuation compared to traditional opioids, though gradual tapering is still recommended when stopping the drug after prolonged use.15PubMed. Appropriate use of tapentadol: focus on the optimal tapering strategy The norepinephrine component may partly explain this: the withdrawal syndrome from tapentadol may not track perfectly with what people expect from opioid withdrawal alone, since the norepinephrine reuptake inhibition introduces its own discontinuation dynamics.
What Makes Tapentadol Dangerous at High Doses
A systematic review of tapentadol toxicity cataloged the serious adverse effects that show up in overdose and high-dose misuse: respiratory depression, confusion, coma, hallucinations, seizures, rapid heart rate, high blood pressure, agitation, tremor, and constricted pupils, among others.16PubMed. Toxicity of tapentadol: a systematic review One documented overdose case involved a man found unresponsive who, after receiving naloxone (the opioid reversal agent), became combative and showed signs consistent with serotonin syndrome despite tapentadol’s supposedly minimal serotonin activity.17PubMed Central. Probable Tapentadol-Associated Serotonin Syndrome After Overdose This suggests that at very high doses, even the “minimal” serotonin effects can become clinically dangerous.
The serotonin angle matters for anyone combining tapentadol with antidepressants, which is relevant to the discussion of recreational use because many people who misuse opioids are also taking psychiatric medications. A study of fatal tapentadol-related poisonings in Australia found that in every single case, other psychoactive drugs were also present. The most commonly detected co-intoxicants were antidepressants (found in about 72% of cases), other opioids (about 67%), sedative-hypnotics (about 64%), and gabapentinoids (about 43%).18PubMed. Characteristics of fatal tapentadol-related toxicity in Australia None of those deaths involved tapentadol alone. The drug becomes far more lethal in combination.
Tamper Resistance of the Extended-Release Tablets
Part of the reason tapentadol’s street abuse numbers stay relatively low may be practical rather than pharmacological. The extended-release formulation was designed with tamper-resistant properties. In laboratory testing, the tablets could not be crushed with two spoons and showed only minimal deformation in a pill crusher, with no pulverization. Even when hammered flat, the tablets didn’t break apart into powder. Intact tablets resisted extraction in most organic solvents, and even hammered tablets required prolonged vigorous shaking to release more than half of the active ingredient.19PubMed. Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: results of in vitro laboratory analyses
For someone trying to snort or inject the drug, these properties create real barriers. You can’t easily grind the extended-release tablets into a powder or dissolve them for injection. The immediate-release formulation is another story; it doesn’t have the same tamper-resistant design and is more straightforward to misuse. This distinction is worth understanding for anyone who encounters tapentadol in a non-medical context.
Why Liver Function Changes Everything
Tapentadol is cleared from the body primarily through a process called glucuronidation in the liver.20PubMed. Comparative metabolism of tramadol and tapentadol: a toxicological perspective If your liver isn’t working well, tapentadol hangs around in your bloodstream much longer and at much higher levels. Pharmacokinetic modeling found that clearance of tapentadol dropped by more than 60% in people with significantly elevated bilirubin, a marker of poor liver function.21PubMed. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain
This is particularly relevant to recreational users who drink heavily or have liver damage from other causes. A dose that produces a mild buzz in someone with a healthy liver could produce dangerously high blood levels in someone whose liver is compromised. The same applies to older adults, whose hepatic function tends to decline with age. Other factors that influence how the drug is processed include sex, body weight, and kidney function, all of which shift the drug’s concentration in the blood to varying degrees.22PubMed. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain
The False Positive Problem on Drug Tests
One practical complication that catches people off guard: tapentadol can trigger a false-positive result for amphetamines on standard urine drug screens. A documented case involved a woman taking tapentadol whose urine tested positive for amphetamines on a common immunoassay. Confirmatory testing with a more precise method found no amphetamines whatsoever, only tapentadol and its metabolite. The cross-reactivity occurred at high concentrations of the drug and its breakdown product.23PubMed Central. Can tapentadol cause a false-positive urine drug screen result for amphetamine?
This is the kind of thing that matters in real life. If you’re taking tapentadol (prescribed or otherwise) and you’re subject to workplace drug testing, probation testing, or pain management compliance monitoring, a false-positive amphetamine result could have serious consequences. Anyone in that situation should make the prescriber and the testing lab aware of the tapentadol use ahead of time. Confirmatory testing can distinguish tapentadol from actual amphetamines, but only if someone thinks to order it.
Polysubstance Use and the Real Risk Profile
The fatality data from Australia underscores a point that cannot be stressed enough: tapentadol-related deaths are overwhelmingly polysubstance events. When antidepressants, benzodiazepines, other opioids, and gabapentinoids show up alongside tapentadol in more than two-thirds of fatal cases, the drug’s lethality is clearly magnified by combinations rather than driven by tapentadol alone.24PubMed. Characteristics of fatal tapentadol-related toxicity in Australia The combination with sedatives is especially dangerous because both tapentadol’s opioid activity and sedatives like benzodiazepines suppress breathing. The norepinephrine component doesn’t protect against respiratory depression; it just adds additional pharmacological unpredictability to an already volatile mix.
Gabapentinoids (gabapentin and pregabalin) deserve specific mention because their presence in over 40% of fatal cases reflects a broader trend in opioid-related deaths. These drugs enhance sedation and respiratory depression in ways that many users don’t anticipate, and they’ve become increasingly common in polydrug fatalities across many opioid types, not just tapentadol. Anyone mixing tapentadol with gabapentin, pregabalin, benzodiazepines, alcohol, or antidepressants is operating in territory where the risk of a fatal outcome is substantially higher than with tapentadol on its own.
The Perceptual Oddities That Set It Apart
The visual effects and time-perception changes reported by some recreational users are unusual among opioids and are worth taking seriously as a distinguishing feature. Traditional opioid highs are typically described in terms of warmth, relaxation, pain relief, and drowsiness. Tapentadol’s norepinephrine activity appears to layer in effects more commonly associated with stimulants or certain antidepressants: heightened sensory input, altered perception, and changes to the sleep-wake boundary (hence the hypnagogic hallucinations mentioned in case reports). These are not the effects most people are prepared for when they take what they think of as “just a painkiller.”
The unpredictability of these perceptual effects also raises the question of what happens in people who already have psychiatric conditions, particularly psychotic disorders or conditions involving perceptual disturbance. If tapentadol at high doses can produce visual and temporal distortions in otherwise healthy individuals, the potential for worsening psychotic symptoms in vulnerable people is a genuine concern that the existing literature hasn’t fully explored. The case series that documented these experiences involved only a handful of patients, so the full range of atypical psychoactive effects from tapentadol misuse remains poorly mapped.